Dataset Information

BioDynaMo: a modular platform for high-performance agent-based simulation.

ABSTRACT:

Motivation

Agent-based modeling is an indispensable tool for studying complex biological systems. However, existing simulation platforms do not always take full advantage of modern hardware and often have a field-specific software design.

Results

We present a novel simulation platform called BioDynaMo that alleviates both of these problems. BioDynaMo features a modular and high-performance simulation engine. We demonstrate that BioDynaMo can be used to simulate use cases in: neuroscience, oncology, and epidemiology. For each use case we validate our findings with experimental data or an analytical solution. Our performance results show that BioDynaMo performs up to three orders of magnitude faster than the state-of-the-art baselines. This improvement makes it feasible to simulate each use case with one billion agents on a single server, showcasing the potential BioDynaMo has for computational biology research.

Availability

BioDynaMo is an open-source project under the Apache 2.0 license and is available at www.biodynamo.org. Instructions to reproduce the results are available in supplementary information.

Supplementary information

Available at https://doi.org/10.5281/zenodo.5121618.

SUBMITTER: Breitwieser L

PROVIDER: S-EPMC8723141 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:IntroductionA Cloud-ORiented Engine for advanced MRI simulations (coreMRI) is presented in this study. The aim was to develop the first advanced MR simulation platform delivered as a web service through an on-demand, scalable cloud-based and GPU-based infrastructure. We hypothesized that such an online MR simulation platform could be utilized as a virtual MRI scanner but also as a cloud-based, high-performance engine for advanced MR simulations in simulation-based quantitative MR (qMR) methods.Methods and resultsThe simulation framework of coreMRI was based on the solution of the Bloch equations and utilized a ground-up-approach design based on the principles already published in the literature. The development of a front-end environment allowed the connection of the end-users to the GPU-equipped instances on the cloud. The coreMRI simulation platform was based on a modular design where individual modules (such as the Gadgetron reconstruction framework and a newly developed Pulse Sequence Designer) could be inserted in the main simulation framework. Different types and sources of pulse sequences and anatomical models were utilized in this study revealing the flexibility that the coreMRI simulation platform offers to the users. The performance and scalability of coreMRI were also examined on multi-GPU configurations on the cloud, showing that a multi-GPU computer on the cloud equipped with a newer generation of GPU cards could significantly mitigate the prolonged execution times that accompany more realistic MRI and qMR simulations.ConclusionscoreMRI is available to the entire MR community, whereas its high performance and scalability allow its users to configure advanced MRI experiments without the constraints imposed by experimentation in a true MRI scanner (such as time constraint and limited availability of MR scanners), without upfront investment for purchasing advanced computer systems and without any user expertise on computer programming or MR physics. coreMRI is available to the users through the webpage https://www.coreMRI.org.

Project description:Viral interferon (IFN) antagonists are a diverse class of viral proteins that counteract the host IFN response, which is important for controlling viral infections. Viral IFN antagonists are often multifunctional proteins that perform vital roles in virus replication beyond IFN antagonism. The critical importance of viral IFN antagonists is highlighted by the fact that almost all viruses encode one of these proteins. Inhibition of viral IFN antagonists has the potential to exert pleiotropic antiviral effects and thus this important protein class represents a diverse plethora of novel therapeutic targets. To exploit this, we have successfully developed and executed a novel modular cell-based platform that facilitates the safe and rapid screening for inhibitors of a viral IFN antagonist of choice. The platform is based on two reporter cell-lines that provide a simple method to detect activation of IFN induction or signaling via an eGFP gene placed under the control of the IFNβ or an ISRE-containing promoter, respectively. Expression of a target IFN antagonist in the appropriate reporter cell-line will block the IFN response and hence eGFP expression. We hypothesized that addition of a compound that inhibits IFN antagonist function will release the block imposed on the IFN response and hence restore eGFP expression, providing a measurable parameter for high throughput screening (HTS). We demonstrate assay proof-of-concept by (i) exploiting hepatitis C virus (HCV) protease inhibitors to inhibit NS3-4A's capacity to block IFN induction and (ii) successfully executing two HTS targeting viral IFN antagonists that block IFN signaling; NS2 and IE1 from human respiratory syncytial virus (RSV) and cytomegalovirus (CMV) respectively, two clinically important viruses for which vaccine development has thus far been unsuccessful and new antivirals are required. Both screens performed robustly and Z' Factor scores of >0.6 were achieved. We identified (i) four hit compounds that specifically inhibit RSV NS2's ability to block IFN signaling by mediating STAT2 degradation and exhibit modest antiviral activity and (ii) two hit compounds that interfere with IE1 transcription and significantly impair CMV replication. Overall, we demonstrate assay proof-of-concept as we target viral IFN antagonists from unrelated viruses and demonstrate its suitability for HTS.